- Home
- BW vs CHRS Comparison
BW vs CHRS Comparison
Compare BW & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BW
- CHRS
- Stock Information
- Founded
- BW 1867
- CHRS 2010
- Country
- BW United States
- CHRS United States
- Employees
- BW N/A
- CHRS N/A
- Industry
- BW Building Products
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BW Industrials
- CHRS Health Care
- Exchange
- BW Nasdaq
- CHRS Nasdaq
- Market Cap
- BW 182.0M
- CHRS 191.3M
- IPO Year
- BW N/A
- CHRS 2014
- Fundamental
- Price
- BW $1.46
- CHRS $1.44
- Analyst Decision
- BW Strong Buy
- CHRS Strong Buy
- Analyst Count
- BW 3
- CHRS 4
- Target Price
- BW $4.50
- CHRS $5.38
- AVG Volume (30 Days)
- BW 1.3M
- CHRS 2.2M
- Earning Date
- BW 11-12-2024
- CHRS 11-06-2024
- Dividend Yield
- BW N/A
- CHRS N/A
- EPS Growth
- BW N/A
- CHRS N/A
- EPS
- BW N/A
- CHRS N/A
- Revenue
- BW $878,224,000.00
- CHRS $304,340,000.00
- Revenue This Year
- BW N/A
- CHRS $2.47
- Revenue Next Year
- BW N/A
- CHRS N/A
- P/E Ratio
- BW N/A
- CHRS N/A
- Revenue Growth
- BW N/A
- CHRS 44.19
- 52 Week Low
- BW $0.75
- CHRS $0.66
- 52 Week High
- BW $2.99
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- BW 34.45
- CHRS 48.85
- Support Level
- BW $1.60
- CHRS $1.44
- Resistance Level
- BW $1.90
- CHRS $1.77
- Average True Range (ATR)
- BW 0.10
- CHRS 0.13
- MACD
- BW -0.01
- CHRS -0.03
- Stochastic Oscillator
- BW 4.40
- CHRS 21.43
About BW Babcock & Wilcox Enterprises Inc.
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.